Supporting education, research and care related to rare diseases is very timely in Europe, with the announcement on December 15 2016 that the European Commission's Board of Member States had approved 23 European Reference Networks (ERNs), including one for rare respiratory diseases (ERN-LUNG; table 1) [3] . Furthermore, in order to share knowledge and expertise more efficiently, the European Union Committee of Experts on Rare Diseases (EUCERD) has adopted recommendations on quality criteria for centres of expertise in rare diseases in member states [4] . Centres of expertise should allow the concentration of both expertise and patient numbers in one place to tackle rare or complex diseases and conditions more effectively [3, 4] . Developing centres of expertise and ERNs in the field of rare diseases was proposed in the European Council recommendation for action in the field of rare diseases and more recently in the cross-border healthcare directive as a means of organising care for the thousands of heterogeneous rare conditions affecting scattered patient populations across Europe [4] .
The ERN-LUNG is a network of European healthcare providers dedicated to ensuring and promoting excellence in care and research for the benefit of patients affected by rare respiratory diseases. ERN-LUNG's vision is to be a European knowledge hub for such diseases and to decrease morbidity and mortality from them in people of all ages. It is a non-profit, international, professional, patient-centric and scientific network and it is committed Europe-wide and globally to the prevention, diagnosis and treatment of rare respiratory diseases through patient care and advocacy, education and research. In keeping with these goals, ERN-LUNG will interact with both national and international organisations which have similar goals. ERN-LUNG is currently made up of 60 centres in 12 countries and is organised into nine core networks representing the diversity of diseases and conditions affecting the respiratory system (figure 2, table 2). The current core networks are interstitial lung diseases [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , cystic fibrosis [22] [23] [24] [25] , pulmonary hypertension [26] [27] [28] [29] [30] [31] , primary ciliary dyskinesia [32] [33] [34] [35] [36] [37] , non-cystic fibrosis bronchiectasis [38] [39] [40] , α 1 -antitrypsin deficiency [41] , mesothelioma [42] , chronic lung allograft dysfunction [43] [44] [45] and "other rare lung diseases" (e.g. pulmonary malformations, congenital central hypoventilation syndrome etc) [46] [47] [48] [49] . In addition to these thematic subgroups, ERN-LUNG is also organised into functional committees whose aims are to tackle overarching topics affecting all of the current and future core networks, including research and clinical trials, ethical issues, registries and biobanks, patient-reported outcomes and quality-of-life, quality management, guidelines and best practice of care, communication and outreach, cross-border care, and training and continued medical education.
The ERN-LUNG's current set-up will evolve with the inclusion of more members and partners after it is formally established. The creation of a ninth core network on "other rare lung diseases" is intended to serve as an intermediate solution to the question of the formal creation of additional core networks over the next 5 years, covering groups that could not formally become core networks in the initial application stage. The strategic plan for ERN-LUNG is set out in a multi-annual work plan submitted in response to the call for Framework Partnership Agreements for the period 2017-2021 (Chafea: HP-ERN-2016). The plan sets out an evaluation strategy that will be followed to review the ERN-LUNG's achievements within the first 5 years of its establishment.
The ERN awarding ceremony will take place on March 9-10, in Vilnius, Lithuania, in the presence of ERN coordinators and patients' representatives. A few weeks later, the ERN-LUNG kick-off meeting will take place on April 4-5 in Frankfurt with all the healthcare providers and patients' representatives attending.
ERN-LUNG board (representatives from all providers, patient groups and other third-party stakeholders)
Functional committees (research and clinical trials committee, ethical issues committee, registries and biobanks committee, patient-recorded outcomes and quality-of-life committee, quality management committee, guidelines and best practice of care committee, communication and outreach committee, cross-border care committee, training and continued medical education committee) The European Respiratory Society has always been very supportive of rare pulmonary disease research, education and care, and the society's publications regularly disseminate novel data and guidelines in these fields [50, 51] . Of note, the society will endorse the 7th International Meeting on Pulmonary Rare Diseases and Orphan Drugs, which will take place in Milan, Italy on February 24-25. This conference, chaired by Dr Sergio Harari, Chief Editor of the European Respiratory Review, is dedicated entirely to rare pulmonary diseases and rare variants of more common pulmonary conditions. The proceedings from this conference will be published in the European Respiratory Review and updates from the ERN-LUNG will feature regularly in the European Respiratory Journal. Rare respiratory diseases are indeed ready for primetime! 
